# CX-908

Source: https://onco.cc/drugs/cx-908/  
OnCo record `cx-908` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CX-908 is an experimental masked T-cell engager from CytomX Therapeutics, in preclinical development for solid tumours.

## Summary

CX-908 is a masked T-cell engager (Probody TCB) from CytomX Therapeutics. A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: CX-908
- Modality: Masked T-cell engager (Probody TCB)
- Mechanism: A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail.

## Sources

- CytomX Therapeutics: cytomx.com: https://cytomx.com/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [CytomX Therapeutics](https://onco.cc/companies/cytomx-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/cx-908.json